Evidence map›Paper›PMID 34762922›Full record

ReviewNeuropharmacology2022

Peripheral versus central insulin and leptin resistance: Role in metabolic disorders, cognition, and neuropsychiatric diseases.

Jennifer M Erichsen, Jim R Fadel, Lawrence P Reagan

Open access · greenAbstract readComparative StudyReview
In one paragraph

Review in Neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Insulin Resistance and Inflammation.International journal of molecular sciences · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Research Progress on Leptin in Metabolic Dysfunction-associated Fatty Liver Disease.Journal of clinical and translational hepatology · 2025
    Review
  13. Article
  14. Article
  15. Dose-finding andMolecular therapy. Methods & clinical development · 2025
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jennifer M ErichsenUniversity of South Carolina School of Medicine, Department of Pharmacology, Physiology, and Neuroscience, Columbia, SC, 29208, USA. Electronic address: jennifer.erichsen@uscmed.sc.edu.
Jim R FadelUniversity of South Carolina School of Medicine, Department of Pharmacology, Physiology, and Neuroscience, Columbia, SC, 29208, USA.
Lawrence P ReaganUniversity of South Carolina School of Medicine, Department of Pharmacology, Physiology, and Neuroscience, Columbia, SC, 29208, USA; Columbia VA Health Care System, Columbia, SC, 29208, USA.
University of South Carolina · US

Funding

Translational Training in Aging and Alzheimer’s Disease Related DisordersT32AG033534 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI STEPHEN B. KRITCHEVSKY · 2009 to 2026
$3.6M
Hypocretin/orexin modulation of cognitive correlates of brain agingR01AG050518 · NIA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI JIM R FADEL · 2015 to 2026
$2.1M
Hypocretin/orexin modulation of cognitive correlates of brain agingRF1AG050518 · NIA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI FADEL, JIM R · 2022 to 2022
$1.1M
Elucidation of the Mechanism Behind the Pro-Cognitive Effects of Intranasal InsulinF31AG066501 · NIA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ERICHSEN, JENNIFER · 2020 to 2021
$71k
Decreased CNS leptin activity in co-morbid depression and obesityI01BX001804 · VA · VETERANS HEALTH ADMINISTRATION · PI REAGAN, LAWRENCE P · 2013 to 2021
–
BLRD VA I01 BX001804BLRD VA I01 BX002664NIA NIH HHS F31 AG066501NIA NIH HHS R01 AG050518NIA NIH HHS RF1 AG050518NIA NIH HHS T32 AG033534
6 · The paper itself

Abstract

Insulin and leptin are classically regarded as peptide hormones that play key roles in metabolism. In actuality, they serve several functions in both the periphery and central nervous system (CNS). Likewise, insulin and leptin resistance can occur both peripherally and centrally. Metabolic disorders such as diabetes and obesity share several key features including insulin and leptin resistance. While the peripheral effects of these disorders are well-known (i.e. cardiovascular disease, hypertension, stroke, dyslipidemia, etc.), the CNS complications of leptin and insulin resistance have come into sharper focus. Both preclinical and clinical findings have indicated that insulin and leptin resistance are associated with cognitive deficits and neuropsychiatric diseases such as depression. Importantly, these studies also suggest that these deficits in neuroplasticity can be reversed by restoration of insulin and leptin sensitivity. In view of these observations, this review will describe, in detail, the peripheral and central functions of insulin and leptin and explain the role of insulin and leptin resistance in various metabolic disorders, cognition, and neuropsychiatric diseases.

Indexed as

AnimalsCognitive DysfunctionHumansInsulinInsulin ResistanceLeptinMental DisordersMetabolic DiseasesInsulinLeptinDiabetesInsulinLeptinMetabolic disordersObesity

Identifiers

PMID34762922
PMCPMC8642294
OpenAlexW3211571713

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.